Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss. The company is also developing AM-125 for the treatment of vestibular disorders; and other pre-clinical stage products comprising AM-102 and AM-123. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EARS
CUSIPN/A
Phone41-41-729-7194
Debt
Debt-to-Equity Ratio-3.12
Current Ratio1.40
Quick Ratio1.40
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.36) per share
Price / Book-2.19
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-24,800,000.00
Net MarginsN/A
Return on Equity-5,833.92%
Return on Assets-82.77%
Miscellaneous
Employees24
Outstanding Shares6,120,000
Auris Medical (NASDAQ:EARS) Frequently Asked Questions
What is Auris Medical's stock symbol?
Auris Medical trades on the NASDAQ under the ticker symbol "EARS."
How were Auris Medical's earnings last quarter?
Auris Medical Holding AG (NASDAQ:EARS) announced its quarterly earnings data on Tuesday, May, 15th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter. View Auris Medical's Earnings History.
When is Auris Medical's next earnings date?
What price target have analysts set for EARS?
1 brokerages have issued 12-month price objectives for Auris Medical's shares. Their predictions range from $5.00 to $5.00. On average, they anticipate Auris Medical's stock price to reach $5.00 in the next year. View Analyst Ratings for Auris Medical.
Who are some of Auris Medical's key competitors?
Some companies that are related to Auris Medical include Pulmatrix (PULM), Flex Pharma (FLKS), IntelliPharmaCeutics Intl (IPCI), Agile Therapeutics (AGRX), Kaya (KAYS), Acasti Pharma (ACST), Jaguar Health (JAGX), Fibrocell Science (FCSC), Cyclacel Pharmaceuticals (CYCC), Bio-Path (BPTH), Prana Biotechnology (PRAN), DelMar Pharmaceuticals (DMPI), ContraVir Pharmaceuticals (CTRV), Dare Bioscience (DARE) and THERAPIX BIOSCI/S (TRPX).
Who are Auris Medical's key executives?
Auris Medical's management team includes the folowing people:
- Dr. Thomas Meyer Ph.D., Founder, Chairman, CEO & MD (Age 50)
- Mr. Hernan Levett, Chief Financial Officer (Age 42)
- Ms. Andrea Braun-Scherhag, Head of Regulatory & Quality Affairs (Age 51)
- Ms. Michelle Aarts Ph.D., Adviser
- Mr. Giles Hardingham Ph.D., Adviser
Has Auris Medical been receiving favorable news coverage?
News articles about EARS stock have been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Auris Medical earned a media sentiment score of 0.16 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 46.07 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Auris Medical's major shareholders?
Auris Medical's stock is owned by many different of institutional and retail investors. Top institutional investors include Sofinnova Ventures Inc (12.77%), Sabby Management LLC (5.60%) and SOFINNOVA VENTURE PARTNERS VIII, L.P. (4.20%). View Institutional Ownership Trends for Auris Medical.
Which institutional investors are buying Auris Medical stock?
How do I buy shares of Auris Medical?
Shares of EARS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Auris Medical's stock price today?
One share of EARS stock can currently be purchased for approximately $0.79.
How big of a company is Auris Medical?
Auris Medical has a market capitalization of $5.14 million. Auris Medical employs 24 workers across the globe.
How can I contact Auris Medical?
Auris Medical's mailing address is BAHNHOFSTRASSE 21, ZUG V8, 6300. The biotechnology company can be reached via phone at 41-41-729-7194 or via email at [email protected]
MarketBeat Community Rating for Auris Medical (EARS)
MarketBeat's community ratings are surveys of what our community members think about Auris Medical and other stocks. Vote "Outperform" if you believe EARS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EARS will underperform the S&P 500 over the long term. You may vote once every thirty days.
